DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gdk66n/pristiq_major) has announced the addition of the "Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Pristiq (desvenlafaxine) is an SNRI antidepressant that was developed by Wyeth, before Wyeth was acquired by Pfizer. Pristiq was launched in the US and Australia in 2008, but is not available in the 5EU and Japan. Pristiq is closely related to Effexor, and more specifically, is the major active metabolite of Effexor. Therefore, despite being a newer SNRI antidepressant, Pristiq will be unable to match the success of Cymbalta and Effexor. Preclinical studies have shown that Pristiq is a potent SNRI, which is believed to cause its antidepressant effects.
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Pristiq including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Pristiq for the top three countries from 2013 to 2023.
- Sales information covered for the US, Spain and Australia.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Pristiq (Desvenlafaxine)
For more information visit http://www.researchandmarkets.com/research/gdk66n/pristiq_major